Current understanding of the role of bosentan in inoperable chronic thromboembolic pulmonary hypertension

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 9, 2006, Pages 1133-1138

  Hughes, Rodney ^a   Jais, Xavier ^b   Suntharalingam, Jay ^c   Humbert, Marc ^b   Parent, Florence ^b   Simonneau, Gerald ^b   Pepke Zaba, Joanna ^a  

^a PAPWORTH HOSPITAL   (United Kingdom)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

^c Papworth Hospital ^*

Author keywords

Bosentan; Chronic thromboembolic pulmonary hypertension; Pulmonary endarterectomy; Pulmonary hypertension

Indexed keywords

BOSENTAN; CYCLOSPORIN; DILTIAZEM; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; ERYTHROMYCIN; FLUCONAZOLE; GLIBENCLAMIDE; PHOSPHODIESTERASE V INHIBITOR; PROSTANOID; SILDENAFIL;

ACUTE DISEASE; BLOOD CLOT LYSIS; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CLINICAL TRIAL; COMORBIDITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FLUSHING; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE FUNCTION; HUMAN; HYPOTENSION; LIVER DYSFUNCTION; LUNG BLOOD FLOW; LUNG EMBOLISM; NOSE CONGESTION; PERIPHERAL EDEMA; PULMONARY ARTERY DISEASE; PULMONARY HYPERTENSION; REVIEW; TREATMENT INDICATION;

ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIN-1; HUMANS; HYPERTENSION, PULMONARY; PULMONARY EMBOLISM; RECEPTORS, ENDOTHELIN; SULFONAMIDES;

EID: 33745477975     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.9.1133     Document Type: Review

References (34)

1. FEDULLO PF, AUGER WR, CHANNICK RN, MOSER KM, JAMIESON SW: Chronic thromboembolic pulmonary hypertension. Clin. Chest Med. (1995) 16(2):353-374.
2. PENGO V, LENSING AW, PRINS MH et al.: Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N. Engl. J. Med. (2004) 350(22):2257-2264.
3. RIEDEL M, STANEK V, WIDIMSKY J, PREROVSKY I: Long term follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data. Chest (1982) 81(2):151-158.
4. HOUK VN, HUFNAGEL CA, MCCLENATHAN JE, MOSER KM: Chronic thrombotic obstruction of major pulmonary arteries, report of a case successfully treated by thrombendarterectomy and a review of the literature. Am. J. Med. (1963) 35:269-282.
5. JAMIESON SW: Pulmonary thromboendarterectomy. Heart (1998) 79(2):118-120.
6. MOSER KM, SPRAGG RG, UTLEY J, DAILY PO: Chronic thrombotic obstruction of major pulmonary arteries. Results of thromboendarterectomy in 15 patients. Ann. Intern. Med. (1983) 99(3):299-304.
7. JAMIESON SW, KAPELANSKI DP, SAKAKIBARA N et al.: Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann. Thorac. Surg. (2003) 76(5):1457-1462.
8. THISTLETHWAITE PA, MO M, MADANI MM: Operative classification of thromboembolic disease determines outcome after pulmonary endarterectomy. J. Thorac. Cardiovasc. Surg. (2002) 124(6):1203-1211.
9. MOSER KM, BLOOR CM: Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest (1993) 103(3):685-692.
10. SIMON M, BATTISTINI B, JOO KIM Y, TSANG J: Plasma levels of endothelin-1, big endothelin-1 and thromboxane following acute pulmonary air embolism. Respir. Physiol. Neurobiol. (2003) 138(1):97-106.
11. SOFIA M, FARAONE S, ALIFANO M et al.: Endothelin abnormalities in patients with pulmonary embolism. Chest (1997) 111(3):544-549.
12. KIM H, YUNG GL, MARSH JJ et al.: Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension. Eur. Respir. J. (2000) 15(4):640-648.
13. BAUER M, WILKENS H, LANGER F, SCHNEIDER SO, LAUSBERG H, SCHAFERS HJ: Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation (2002) 105(9):1034-1036.
14. HUMBERT M, SITBON O, SIMONNEAU G: Treatment of pulmonary arterial hypertension. N. Engl. J. Med. (2004) 351(14):1425-1436.
15. PROVENCHER S, SITBON O, SIMONNEAU G: Treatment of pulmonary arterial hypertension with bosentan: from pathophysiology to clinical evidence. Expert Opin. Pharmacother. (2005) 6(8):1337-1348.
16. BRESSER P, FEDULLO PF, AUGER WR et al.: Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension. Eur. Respir. J. (2004) 23(4):595-600.
17. GHOFRANI HA, SCHERMULY RT, ROSE F et al.: Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am. J. Respir. Crit. Care Med. (2003) 167(8):1139-1141.
18. NAGAYA N, SHIMIZU Y, SATOH T et al.: Oral beraprost sodium improves exercise capacity and ventilatory efficiency in patients with primary or thromboembolic pulmonary hypertension. Heart (2002) 87(4):340-345.
19. ROIG FIGUEROA V, HERRERO PEREZ A, DE LA TORRE FERRERA N, HERNANDEZ GARCIA E, ALLER ALVAREZ JL, PARA CABELLO J: Iloprost for chronic thromboembolic pulmonary hypertension. Arch. Bronconeumol. (2004) 40(7):326-328.
20. ONO F, NAGAYA N, OKUMURA H et al.: Effect of orally active prostacyclin analogue on survival in patients with chronic thromboembolic pulmonary hypertension without major vessel obstruction. Chest (2003) 123(5):1583-1588.
21. SCELSI L, GHIO S, CAMPANA C et al.: Epoprostenol in chronic thromboembolic pulmonary hypertension with distal lesions. Ital. Heart J. (2004) 5(8):618-623.
22. RUBIN LJ, BADESCH DB, BARST RJ et al.: Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. (2002) 346(12):896-903.
23. GALIE N, HINDERLITER AL, TORBICKI A et al.: Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J. Am. Coll. Cardiol. (2003) 41(8):1380-1386.
24. SITBON O, MCLAUGHLIN VV, BADESCH DB et al.: Survival in patients with Class III idiopathic pulmonary arterial hypertension treated with first-line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax (2005) 60(12):1025-1030.
25. SITBON O, BADESCH DB, CHANNICK RN et al.: Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest (2003) 124(1):247-254.
26. KIM NH, LJ RUBIN: Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension. J. Cardiovasc. Pharmacol. Ther. (2002) 7(1):9-19.
27. DINGEMANSE J, PL VAN GIERSBERGEN: Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin. Pharmacokinet. (2004) 43(15):1089-1115.
28. LIEFELDT L, VAN GIERSBERGEN PL, DINGEMANSE J et al.: Treatment of secondary pulmonary hypertension with bosentan and its pharmacokinetic monitoring in ESRD. Am. J. Kidney Dis. (2004) 43(5):923-926.
29. PAUL GA, GIBBS JS, BOOBIS AR, ABBAS A, WILKINS MR: Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br. J. Clin. Pharmacol. (2005) 60(1):107-112.
30. HOEPER M, KIELY D, CARLSEN J et al.: Safety profile of pulmonary arterial hypertension patients treated with bosentan and sildenafil: results from the European surveillance program. Proc. Am. Thorac. Soc. (2005) 2:A300.
31. HUGHES R, GEORGE P, PARAMESHWAR J et al.: Bosentan in inoperable chronic thromboembolic pulmonary hypertension. Thorax (2005) 60(8):707.
32. HOEPER MM, KRAMM T, WILKENS H et al.: Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest (2005) 128(4):2363-2367.
33. BONDERMAN D, NOWOTNY R, SKORO-SAJER N et al.: Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest (2005) 128(4):2599-2603.
34. HUGHES R et al.: Bosentan for the treatment of distal chronic thromboembolic pulmonary hypertension: outcomes at one year. Thorax (2005) 60(Suppl. II):ii89.